Eric H. Zanelli, PhD

Dr. Zanelli joined Peptimmune in 2003 as vice president of research and is a leading immunologist and HLA expert with experience in therapeutic development. Prior to Peptimmune, Dr. Zanelli was at Praecis Pharmaceuticals and Cardion AG, applying his expertise in autoimmune disease to the development of new treatments for rheumatoid arthritis, Type I diabetes, and multiple sclerosis. Eric received a PhD in Immunology from the University of Aix-Marseille II, France and was a postdoctoral fellow in the laboratory of Dr. Chella David at the Mayo Clinic, MN. His work was mostly related to the identification of genes involved in antigen processing and the role of MHC Class II gene polymorphism in the predisposition to rheumatoid arthritis. From 1996 to 2001, Eric was assistant professor at the Leiden University Medical Center in the Netherlands. While there, he continued his investigation of the role of MHC Class II genes in predisposition to autoimmune diseases and their value as clinical predictors of disease severity. Eric has over forty publications in peer-reviewed scientific journals.